<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of infections in hematopoietic cell transplant recipients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of infections in hematopoietic cell transplant recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of infections in hematopoietic cell transplant recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Wingard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allogeneic hematopoietic cell transplant (HCT) recipients are at increased risk for a variety of infections based upon their degree of immunosuppression and exposures. Autologous HCT recipients are also at increased risk for infection, although to a lesser degree than those who have undergone allogeneic HCT.</p><p>The term "hematopoietic cell transplantation" will be used throughout this topic review as a general term to cover transplantation of hematopoietic cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). (See  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p>Patients can develop a range of bacterial, fungal, viral, and/or parasitic infections following HCT. Infection in HCT recipients is associated with high morbidity and mortality. Thus, prevention of infection is a major goal, which involves determination of risk, careful selection of donors, prophylactic and/or pre-emptive antimicrobial therapy, immunization, and additional measures (eg, infection control).</p><p>The prevention of certain infections in HCT recipients will be discussed here; prophylaxis of bacterial infections, invasive fungal infections, and viral infections are discussed in greater detail separately. The evaluation for infection before HCT and an overview of infections following HCT are also presented separately. (See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a> and  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H22976505"><span class="h1">EVALUATION BEFORE HCT</span><span class="headingEndMark"> — </span>The pretransplantation evaluation is designed to prevent posttransplant infections by excluding unsuitable donors and defining specific infection control policies and antimicrobial prophylaxis and therapy, which will be necessary after transplantation. Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the HCT donor or candidate. Some tests are recommended for all HCT donors and candidates, whereas others are appropriate in selected individuals with epidemiologic risk factors  (<a class="graphic graphic_table graphicRef56453" href="/d/graphic/56453.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. Serologic testing is used as an indicator of significant past exposures.</p><p>The evaluation for HCT candidates is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>.)</p><p>Donor selection is discussed below. (See <a class="local">'Donor selection'</a> below.)</p><p class="headingAnchor" id="H82951878"><span class="h1">TIMELINE FOR INFECTIONS</span><span class="headingEndMark"> — </span>The types of infections to which HCT recipients are most vulnerable can be roughly divided based upon the time elapsed since transplantation. The three periods are:</p><p class="bulletIndent1"><span class="glyph">●</span>Pre-engraftment – From transplantation to approximately day 30</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early postengraftment – From engraftment to day 100</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late postengraftment – After day 100</p><p></p><p>In general, allogeneic HCT recipients are at risk for infection during all three periods  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>), whereas autologous HCT recipients are typically only vulnerable to infection during the pre- and immediate postengraftment periods  (<a class="graphic graphic_figure graphicRef64491" href="/d/graphic/64491.html" rel="external">figure 2</a>). During each of these time periods, patients can develop bacterial, fungal, viral, and/or parasitic infections, although certain pathogens tend to cause disease during some of these periods more than others  (<a class="graphic graphic_table graphicRef50318" href="/d/graphic/50318.html" rel="external">table 2</a>).</p><p>This division into time periods is artificial, but it is helpful in the management of HCT recipients. The timing and length of interval of each of these phases may vary according to the source of stem cells, degree of human leukocyte antigen (HLA) and minor histocompatability antigen match, type and intensity of conditioning regimen used, and any manipulation the graft has had prior to transplant, immunosuppressive therapy (especially glucocorticoids), and the presence of graft-versus-host disease. </p><p>The timeline for infections is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Timeline for infections'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HIGH-RISK PATIENTS</span><span class="headingEndMark"> — </span>It is important to identify the population at high risk for infections and also the magnitude of and the period of maximum risk in order to identify those patients likely to benefit from prophylaxis  (<a class="graphic graphic_table graphicRef70011" href="/d/graphic/70011.html" rel="external">table 3</a>).</p><p>There are three factors that interact to determine the risk of infection in HCT recipients  (<a class="graphic graphic_figure graphicRef50448" href="/d/graphic/50448.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The patient's net state of immunosuppression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient's exposure to pathogens</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of organ damage</p><p></p><p class="headingAnchor" id="H412374168"><span class="h1">GENERAL STRATEGIES TO REDUCE RISK</span><span class="headingEndMark"> — </span>This section discusses general strategies to reduce the risk of infection following HCT. An overview of the risk of infection following HCT is presented separately. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Risk of infection'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Donor selection</span><span class="headingEndMark"> — </span>Donor selection is critical to reducing the risk of complications that increase the risk for infections following allogeneic HCT including graft-versus-host disease (GVHD), graft failure, and delayed immune reconstitution [<a href="#rid3">3</a>]. Transplantation of stem cells from donors who are not fully histocompatible by high-resolution matching for human leukocyte antigen (HLA) gene donor cells at the A, B, C, and DR loci is more frequently associated with graft failure and GVHD [<a href="#rid4">4</a>]. Donor selection is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor/recipient cytomegalovirus (CMV) serostatus</strong> – The risk of posttransplant CMV infection and CMV disease is significantly influenced by both donor and recipient CMV serostatus, and the serostatus should determine the appropriate prophylaxis or pre-emptive strategy. A recipient who is CMV seropositive and receives a graft from a donor who is CMV seronegative (CMV D-/R+) is at greatest risk for the development of CMV disease after transplant. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Cytomegalovirus'</a> and  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'CMV status'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor/recipient hepatitis B virus serostatus</strong> – Active hepatitis can occur after transplant if either the donor or recipient is seropositive. Monitoring and prophylaxis strategies are discussed separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Hepatitis B virus'</a> and  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H1170632447"><span class="h2">Pre-HCT testing</span><span class="headingEndMark"> — </span>To protect the HCT recipient from acquiring various infections from the donor, both the donor and recipient must undergo a history and physical examination as well as screening tests prior to HCT  (<a class="graphic graphic_table graphicRef56453" href="/d/graphic/56453.html" rel="external">table 1</a>). This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H1170632462"><span class="h2">Conditioning regimen and dose of hematopoietic cells</span><span class="headingEndMark"> — </span>Because persistence of host T cells or natural killer cells may cause graft rejection (and hence increase the risk for infection), an effective conditioning regimen should be used. The infusion of an adequate number of stem cells is critical for prompt hematopoietic recovery in both autologous and allogeneic HCT recipients, especially in patients receiving reduced intensity conditioning and patients receiving grafts from mismatched donors. (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a> and  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H1170632609"><span class="h2">Avoidance of excessive immunosuppression and myelosuppression</span><span class="headingEndMark"> — </span>Glucocorticoids are generally avoided as prophylaxis for GVHD. When needed to treat GVHD, the lowest possible dose of glucocorticoids should be used followed by a rapid taper, and every effort should be made to ensure the proper diagnosis of GVHD prior to commencing glucocorticoids. (See  <a class="medical medical_review" href="/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/3550.html" rel="external">"Treatment of chronic graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease", section on 'Introduction'</a>.)</p><p>It is also important to avoid the prolonged use of potentially myelosuppressive drugs, when possible, and to adjust their doses carefully when used. Examples of such drugs are <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and, occasionally, the H2 blockers and intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>.</p><p class="headingAnchor" id="H5"><span class="h1">ANTIMICROBIAL PROPHYLAXIS OR PRE-EMPTIVE THERAPY</span></p><p class="headingAnchor" id="H6"><span class="h2">Definitions</span><span class="headingEndMark"> — </span>Approaches to the prevention of infection in HCT recipients include primary prophylaxis, secondary prophylaxis, and pre-emptive therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prophylaxis</strong> – Primary prophylaxis involves the administration of an antimicrobial drug to prevent infection in patients at increased risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prophylaxis</strong> – Secondary prophylaxis involves the administration of prophylactic doses of an antimicrobial drug to prevent recurrent infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-emptive therapy</strong> – Pre-emptive therapy involves starting antimicrobial therapy based upon screening with a sensitive assay (eg, polymerase chain reaction [PCR]) in an attempt to detect early infection. The goal of pre-emptive therapy is to avoid progression to invasive disease. Pre-emptive therapy may be favored over prophylaxis when the antimicrobial therapy is particularly toxic (eg, for cytomegalovirus). (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Pre-emptive therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1170632793"><span class="h2">Timing of antimicrobial prophylaxis</span><span class="headingEndMark"> — </span>Antimicrobial prophylaxis should be initiated at the beginning of the risk period, typically with the conditioning regimen or at the time of stem cell infusion (to avoid deleterious interactions with the conditioning regimen) but, in case of myelosuppressive antimicrobials, such as <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, at the time of engraftment and should be continued throughout the period at risk for infection.</p><p class="headingAnchor" id="H7"><span class="h2">Antibacterial prophylaxis</span></p><p class="headingAnchor" id="H855870674"><span class="h3">Before engraftment</span><span class="headingEndMark"> — </span>Antibacterial prophylaxis with a fluoroquinolone has been shown in randomized trials and meta-analyses to reduce all-cause mortality, infection-related mortality, fever, and infections in high-risk neutropenic patients, including allogeneic HCT recipients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloablative allogeneic HCT</strong> – Based upon the available data, we suggest fluoroquinolone prophylaxis for patients undergoing allogeneic HCT who have received myeloablative conditioning regimens. If a fluoroquinolone is contraindicated, a third-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9224" href="/d/drug information/9224.html" rel="external">cefpodoxime</a>, can be used although there are few studies supporting its use [<a href="#rid5">5</a>]. Generally, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> is avoided during the pre-engraftment period due to the concern for myelosuppression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced-intensity and nonmyeloablative conditioning allogeneic HCT</strong> – This type of HCT is generally associated with a short period of neutropenia and, therefore, there is typically no need for antibiotic prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT</strong> – Antibacterial prophylaxis is sometimes given to autologous HCT recipients transplanted for hematologic malignancies who receive intensive conditioning regimens, but the degree of mucosal injury of many of the conditioning regimens is less severe and the shorter time to engraftment make the need for prophylaxis less clear than for allogeneic HCT recipients. Autologous HCT recipients who have received or will receive immunosuppressive therapies increasing the risk for bacterial infections may also be given antibacterial prophylaxis. The decision of whether to give antibacterial prophylaxis to autologous HCT recipients should be made on a case-by-case basis.</p><p></p><p>There are several potential downsides to using fluoroquinolone prophylaxis, including toxicities and the potential for promoting resistance.</p><p>The evidence to support antibacterial prophylaxis in HCT recipients is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'Antibacterial prophylaxis'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">After engraftment</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis should generally be stopped at neutrophil engraftment. However, allogeneic HCT recipients who develop chronic graft-versus-host disease (GVHD) are at substantial risk for serious infection with encapsulated bacteria, especially <em>Streptococcus pneumoniae</em>, and they should receive prolonged antibiotic prophylaxis [<a href="#rid1">1</a>]. The optimal duration of prophylaxis against <em>S. pneumoniae</em> and other encapsulated bacteria is not clear. We continue it for as long as the patient is receiving active immunosuppressive therapy (ie, treatment for GVHD), whereas some centers continue it for a longer period beyond cessation of active immunosuppressive therapy. Antibiotics with activity against encapsulated bacteria include penicillin, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, but rates of resistance to these agents vary in different geographic regions. The choice of antibacterial drug should be based upon local resistance patterns. In areas with a low rate of resistance to penicillin, we favor penicillin.</p><p class="headingAnchor" id="H1105848716"><span class="h2">Antifungal prophylaxis</span><span class="headingEndMark"> — </span>Both yeasts and molds cause serious invasive fungal infections in HCT recipients. Prior to the routine use of antifungal prophylaxis, <em>Candida</em> spp accounted for the majority of fungal infections that occurred during the pre-engraftment period of HCT, followed by <em>Aspergillus</em> spp. HCT recipients are at highest risk for <em>Candida</em> infections during the pre-engraftment period  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). <em>Aspergillus</em> is the most common mold pathogen in HCT recipients, occurring most commonly during the postengraftment period in allogeneic HCT recipients with severe GVHD.</p><p>Antifungal prophylaxis targeting either <em>Candida</em> spp alone or <em>Candida</em> spp plus molds is generally recommended in all HCT recipients. The evidence to support this practice and specific recommendations about antifungal prophylaxis are presented separately. (See  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Pneumocystis prophylaxis</span><span class="headingEndMark"> — </span>For allogeneic HCT recipients, we recommend that prophylaxis against <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>) pneumonia (PCP) be started after neutrophil engraftment and continued for as long as immunosuppressive therapy is given [<a href="#rid1">1</a>]. The typical duration of PCP prophylaxis is six months in allogeneic HCT recipients but is longer in those requiring treatment for GVHD. Early discontinuation of PCP prophylaxis in allogeneic HCT recipients has been associated with PCP [<a href="#rid6">6</a>].</p><p>Among autologous HCT recipients, PCP prophylaxis should be considered for those with underlying hematologic malignancies such as lymphoma, myeloma, or leukemia, those receiving myeloablative conditioning regimens, those with graft manipulations (eg, CD34 selection), those receiving high-dose glucocorticoids, and those who have recently received a purine analog (eg, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>). In autologous HCT recipients, when PCP prophylaxis is indicated, it is typically continued for three to six months following transplantation (or longer for those requiring immunosuppressive drugs).</p><p>TMP-SMX is the preferred regimen because it appears to be the most efficacious; breakthrough PCP infections occur more frequently with other agents [<a href="#rid1">1,7</a>]. TMP-SMX also has activity against <em>Toxoplasma gondii</em>, <em>Nocardia</em> spp, <em>Listeria monocytogenes</em>, and various respiratory and enteric pathogens. Because of the concern about myelosuppression and the low risk of PCP during the first month after HCT, TMP-SMX is generally started after engraftment. It is continued until immunosuppressive therapy is completed.</p><p>PCP prophylaxis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Toxoplasma gondii prophylaxis</span><span class="headingEndMark"> — </span>Toxoplasmosis is an uncommon (&lt;1 percent) but potentially fatal opportunistic parasitic infection that can occur in HCT recipients, particularly in endemic areas [<a href="#rid8">8,9</a>]. Most cases of toxoplasmosis occur due to reactivation in allogeneic HCT recipients, particularly in those with GVHD or in umbilical cord transplant recipients [<a href="#rid10">10-16</a>]. Rare cases of donor-derived infections have been reported [<a href="#rid17">17</a>].</p><p>Although toxoplasmosis has been reported following autologous HCT [<a href="#rid18">18</a>], the risk is very low unless CD34 selection is performed or additional T cell immunosuppressive therapies are given [<a href="#rid19">19,20</a>].</p><p>As noted above, allogeneic HCT recipients should receive TMP-SMX for PCP prophylaxis from engraftment until immunosuppressive therapy is discontinued; TMP-SMX is also effective prophylaxis for toxoplasmosis. For patients who cannot take TMP-SMX, alternative (but less well-studied) prophylaxis regimens include <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, pyrimethamine plus <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>, or pyrimethamine and sulfadoxine plus leucovorin [<a href="#rid1">1,21</a>].</p><p>For patients who cannot take TMP-SMX, an alternative to using a prophylactic regimen other than TMP-SMX is to screen high-risk (GVHD, umbilical cord blood graft) <em>Toxoplasma</em>-seropositive patients with quantitative PCR following transplantation [<a href="#rid1">1,15,22</a>], with initiation of pre-emptive therapy in patients who have a positive PCR assay.</p><p class="headingAnchor" id="H31"><span class="h2">Tuberculosis prophylaxis</span><span class="headingEndMark"> — </span>Prophylaxis against tuberculosis (TB) in HCT recipients should be reserved for patients identified as high risk during the pretransplant evaluation. (See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation", section on 'Screening for tuberculosis'</a>.)</p><p>Although there are no data regarding the efficacy of prophylaxis of TB in HCT recipients, prophylaxis is recommended for individuals at increased risk for TB reactivation given the risk of reactivation following HCT [<a href="#rid1">1,23</a>].</p><p>We suggest <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> (INH) prophylaxis in the HCT candidates or recipients who [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Have been exposed to an individual with active sputum smear-positive pulmonary or laryngeal TB, regardless of the HCT candidate’s or recipient’s <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) or interferon-gamma release assay (IGRA) status <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have a positive TST result, regardless of prior Bacille-Calmette Guérin (BCG) status, without previous treatment for latent TB and with no evidence of active TB <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have a positive IGRA result, without previous treatment for latent TB and with no evidence of active TB</p><p></p><p>INH prophylaxis should generally be initiated at the completion of the conditioning regimen; in some patients, it can be initiated prior to conditioning if the agents in the conditioning regimen do not have significant interactions with INH and if the patient is thought to be at particularly high risk of TB reactivation [<a href="#rid1">1</a>]. Drug interactions, especially with the mold-active azoles, can lead to significant toxicity, and concomitant administration should be avoided. The treatment of latent TB is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p>Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p class="headingAnchor" id="H348778743"><span class="h2">Strongyloides prophylaxis</span><span class="headingEndMark"> — </span>HCT candidates with pretransplant screening tests positive for <em>Strongyloides stercoralis</em> or those with unexplained eosinophilia and a travel or residence history suggesting exposure to <em>S. stercoralis</em> should receive empiric treatment prior to HCT with <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg per day orally daily for two consecutive days, repeat after two weeks) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1105849631"><span class="h2">Antiviral prophylaxis or pre-emptive therapy</span><span class="headingEndMark"> — </span>Viruses of major importance in HCT recipients include members of the herpesvirus family (herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpes virus 6), respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus, adenovirus, SARS-CoV-2), and BK virus. Antiviral prophylaxis or pre-emptive therapy against some of these viruses is recommended for HCT recipients; this is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">ADDITIONAL MEASURES</span><span class="headingEndMark"> — </span>Other important strategies should be employed to reduce the risk of infection in HCT recipients, including infection control measures, immunizations, and others.</p><p class="headingAnchor" id="H412374348"><span class="h2">Infection control measures</span><span class="headingEndMark"> — </span>Effective infection control measures can reduce exposure of HCT recipients to potential nosocomial pathogens. Patients and health care workers should be educated about the risk of and methods to prevent acquisition of these organisms. The following recommendations have been adapted from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astctjournal.org%2Farticle%2FS1083-8791%2809%2900300-0%2Fpdf&amp;token=j%2BtF41plvYHq0KcVLVNCgpPagNM%2FYPfGRefJ1z1cXWTbTTkudQXqMSxdLi84Rphe66HzsSHMB3rVLTtg8DvCBQ%2BfmH50QUm1TzANDy07U48%3D&amp;TOPIC_ID=1397" target="_blank">2009 HCT guidelines</a>; our recommendations are generally in keeping with those guidelines [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protective isolation and room ventilation</strong> – Protective isolation should be used during hospitalization for all allogenic HCT recipients, especially during the early phases after HCT, and can also be used for autologous HCT recipients, depending on the availability of rooms in which protective isolation measures can be implemented. </p><p></p><p>Generally, the following measures should be used for room ventilation when protective isolation is indicated: ≥12 air exchanges per hour, high efficiency particulate air (HEPA) filters, directed airflow (so that air intake occurs at one side of the room and air exhaust occurs at the opposite side), positive air pressure differential between the patient's room and the hallway, well-sealed rooms, continuous pressure monitoring, and self-closing doors to maintain constant pressure differentials. The use of laminar airflow remains controversial because the possible benefit remains unclear [<a href="#rid24">24</a>]; laminar airflow is not recommended for newly constructed patient rooms. However, for patients with infections that can be transmitted via airborne particles (eg, SARS-CoV-2, disseminated zoster, pulmonary tuberculosis), a negative air pressure differential should be used to help prevent transmission to other patients and hospital staff.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Construction or renovation</strong> – If construction or renovation occurs, intensified mold control measures should be put into place to minimize fungal spore counts in patient rooms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cleaning</strong> – HCT units should be cleaned at least daily with special attention to dust control. Selection of furnishings should focus on creating and maintaining a dust-free environment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolation and barrier precautions </strong>– Published guidelines for hospital isolation should be followed to prevent health care–associated infections [<a href="#rid25">25</a>]. At a minimum, standard precautions should be used. Standard precautions include hand hygiene and appropriate personal protective equipment (gloves, surgical masks or eye and face protection, and gowns) during procedures that are likely to generate splashes or sprays of blood, body fluids, secretions or excretions, or cause soiling of clothing. We use gloves and masks during respiratory virus outbreaks and during respiratory virus season in an attempt to further reduce the risk of transmission of respiratory viruses from health care workers and visitors to HCT recipients. Some centers use gloves and masks year-round.</p><p></p><p class="bulletIndent1">Most studies have failed to establish a clear benefit for masks in protecting either other patients or health care workers [<a href="#rid26">26-28</a>]. However, two studies did show a reduction in respiratory virus infections among HCT recipients when masks were worn by all individuals who had direct contact with the patients [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1">When an HCT recipient is suspected of having or proven to have an infection requiring additional precautions (eg, airborne, droplet, or contact precautions), they should be implemented as indicated. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Infection control'</a>.)</p><p></p><p class="bulletIndent1">Although there is insufficient evidence establishing its efficacy, HCT recipients may benefit from wearing masks or N95 respirators when they are outside of their hospital rooms, especially when hospital construction or renovation is occurring.</p><p></p><p class="bulletIndent1">After discharge, we advise HCT recipients to wear masks in doctors’ offices and waiting rooms (but not in homes or outdoors) during the first three months following HCT or longer if they are receiving treatment for graft-versus-host disease (GVHD). We also advise avoidance of large crowds and avoidance of dusty, windy outdoor venues. We suggest that HCT recipients shop and dine out at times when they can avoid close contact with individuals other than their caregivers. The efficacy of these measures has not been established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hand hygiene</strong> – Hand hygiene is the mainstay of infection prevention in the hospital and is an essential element of standard precautions for all patients, including HCT recipients. Hand hygiene involves the use of alcohol-based hand rubs and/or handwashing with soap and water. In the absence of visible soiling of hands or contact with spore-forming organisms (eg, <em>Clostridioides</em> <em>difficile</em>), the preferred method of hand hygiene is with an alcohol-based hand rub because of its superior microbicidal activity, reduced drying of the skin, and convenience. When hands are visibly dirty or when the patient has infection with a spore-forming organism, they should be washed thoroughly using soap and water. (See  <a class="medical medical_review" href="/d/html/2687.html" rel="external">"<i>Clostridioides difficile</i> infection: Prevention and control", section on 'Hand hygiene'</a> and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Care of intravascular catheters</strong> – Health care workers should follow established protocols for preventing intravascular catheter-associated infections. (See  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of plants and flowers</strong> – Plants and dried or fresh flowers should not be allowed in hospital rooms during conditioning or after HCT to reduce possible exposure to mold and bacteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disinfection of toys and play areas</strong> – Toys and play areas should be cleaned and disinfected frequently according to published recommendations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food safety</strong> – Although not well studied, we suggest that HCT recipients receive a diet less likely to expose HCT recipients to microbes than a usual diet. Examples of foods to avoid include raw or undercooked meat, poultry, fish, game, tofu; unpasteurized or raw milk; milk products made from unpasteurized or raw milk; and raw fruits and vegetables.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herbal/naturopathic supplements</strong> – We advise that HCT recipients avoid herbal/naturopathic supplements, in part because they are often contaminated with molds and other pathogens and they have been associated with invasive mold infections in HCT recipients [<a href="#rid31">31,32</a>].</p><p></p><p>Infection control measures for HCT recipients, including recommendations for safe living following hospital discharge after HCT, are discussed in greater detail in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astctjournal.org%2Farticle%2FS1083-8791%2809%2900300-0%2Fpdf&amp;token=j%2BtF41plvYHq0KcVLVNCgpPagNM%2FYPfGRefJ1z1cXWTbTTkudQXqMSxdLi84Rphe66HzsSHMB3rVLTtg8DvCBQ%2BfmH50QUm1TzANDy07U48%3D&amp;TOPIC_ID=1397" target="_blank">2009 HCT guidelines</a>.</p><p class="headingAnchor" id="H293789666"><span class="h2">Chlorhexidine bathing</span><span class="headingEndMark"> — </span>Bathing patients daily with <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> gluconate, an antiseptic agent with broad-spectrum activity against many organisms, has been shown to be an effective method of decreasing both hospital-acquired infections and colonization with drug-resistant organisms, primarily among patients in the intensive care unit (ICU). Benefit has also been shown in HCT recipients [<a href="#rid33">33</a>]. We suggest chlorhexidine bathing for all HCT recipients.</p><p>In a trial that included over 7000 patients in both ICU and HCT units, there was a 23 percent reduction in the overall rate of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and vancomycin-resistant enterococci (VRE) acquisition with daily bathing with 2% chlorhexidine-impregnated washcloths compared with non-impregnated washcloths (5.1 versus 6.6 cases per 1000 patient-days, respectively) as well as a 28 percent reduction in the rate of hospital-acquired bloodstream infections (4.8 versus 6.6 cases per 1000 patient-days, respectively) [<a href="#rid33">33</a>]. The effect was greater among patients with a longer length of hospital stay and was predominantly driven by reduction in VRE rather than MRSA acquisition. Of note, the reduction in bloodstream infections with <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> use was greatest for coagulase-negative staphylococci and fungal infections; there was not a significant reduction in the incidence of central venous catheter–associated bloodstream infections involving gram-negative organisms, VRE, or MRSA.</p><p><a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">Chlorhexidine</a> bathing in ICU patients is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3810.html" rel="external">"Nosocomial infections in the intensive care unit: Epidemiology and prevention", section on 'Patient bathing/decolonization'</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Blood products</span><span class="headingEndMark"> — </span>To prevent transfusion-transmitted cytomegalovirus (CMV) disease in CMV-seronegative recipients whose donor is also CMV seronegative, blood products that are either obtained from CMV-seronegative donors or leukocyte-depleted should be used [<a href="#rid34">34</a>]. </p><p>Iron overload, which may be caused by large numbers of red blood cell (RBC) transfusions, adversely affects the survival of HCT recipients, increasing the likelihood of infections and acute GVHD [<a href="#rid35">35,36</a>]. Transfusion of RBCs should therefore be minimized when possible. Several retrospective studies suggest iron overload may be associated with increased risk for posttransplant fungal and bacterial infection.</p><p class="headingAnchor" id="H34"><span class="h2">Immunomodulation</span><span class="headingEndMark"> — </span>Various colony-stimulating factors (CSFs) and cytokines have been evaluated to improve the host's immune defenses. These agents include granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF; <a class="drug drug_general" data-topicid="9878" href="/d/drug information/9878.html" rel="external">sargramostim</a>), macrophage colony-stimulating factor (M-CSF), and interferon-gamma-1b. Of these, we suggest only the use of CSFs and only in selected patients, as discussed below. (See  <a class="medical medical_review" href="/d/html/16355.html" rel="external">"Strategies for immune reconstitution following allogeneic hematopoietic cell transplantation", section on 'Therapeutic strategies to improve immune reconstitution'</a>.)</p><p class="headingAnchor" id="H73974675"><span class="h3">Colony stimulating factors</span><span class="headingEndMark"> — </span>We typically give G-CSF at a dose of 5 mcg/kg per day only to autologous HCT recipients who receive a suboptimal stem cell dose (eg, &lt;5 million CD34+ cells/kg) and to allogeneic or autologous HCT recipients who have delayed neutrophil engraftment or whose white blood cell counts drop because of drugs (eg, <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>) or infection.</p><p>G-CSF and GM-CSF shorten time to engraftment, especially when the stem cell content of the graft is suboptimal after autologous HCT [<a href="#rid37">37-39</a>]. In a meta-analysis, CSFs were associated with a small reduction in the risk of documented infections but did not affect infection-related mortality or treatment-related mortality [<a href="#rid40">40</a>]. At least one trial in allogeneic HCT recipients suggested decreased survival in patients who received G-CSF [<a href="#rid41">41</a>]. Thus, the use of growth factors is controversial in the setting of allogeneic HCT. (See  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation", section on 'Growth factor support'</a>.)</p><p class="headingAnchor" id="H37"><span class="h2">Intravenous immune globulin</span><span class="headingEndMark"> — </span>We do not recommend the routine use of intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) in HCT recipients [<a href="#rid1">1</a>], as a meta-analysis of randomized trials did not show a benefit in terms of survival, infection prevention, or other transplant complications [<a href="#rid42">42</a>].</p><p>We check immunoglobulin G (IgG) levels in allogeneic HCT recipients with bacteremia or recurrent sinopulmonary infections and administer <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> to those with low serum IgG levels (eg, &lt;300 to 500 mg/dL) [<a href="#rid1">1</a>]. The dose and frequency needed to maintain adequate levels (eg, &gt;500 to 700 mg/dL). Thresholds for IVIG treatment also varies among institutions and experts. The half-life of IVIG in HCT recipients is shorter (approximately 1 to 10 days) than in other patients (approximately 18 to 23 days) [<a href="#rid1">1,43-45</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> is best illustrated by reports of patients with common variable immunodeficiency (CVID). As an example, in a retrospective study of patients with CVID receiving IVIG, there was a higher incidence of serious infections (particularly pneumonia) in patients with IgG trough levels &lt;400 mg/dL than in those with higher levels [<a href="#rid46">46</a>]. IVIG is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a> and  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a> and  <a class="medical medical_review" href="/d/html/3952.html" rel="external">"Treatment and prognosis of common variable immunodeficiency", section on 'Immune globulin replacement therapy'</a>.)</p><p class="headingAnchor" id="H334179693"><span class="h2">Immunization</span></p><p class="headingAnchor" id="H769298993"><span class="h3">Active immunization</span><span class="headingEndMark"> — </span>Following transplantation, HCT recipients typically lose immunity to pathogens against which they were previously immunized. Thus, HCT recipients should be immunized against a number of pathogens following the return of immune competence  (<a class="graphic graphic_table graphicRef91882" href="/d/graphic/91882.html" rel="external">table 4</a>). Other strategies for preventing infections in HCT recipients include pretransplant vaccination of HCT candidates with the usual vaccines that are indicated based upon age, vaccination history, and exposure history; and vaccination of household contacts. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H769298999"><span class="h3">Passive immunization</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or virus-specific immunoglobulins (eg, <a class="drug drug_general" data-topicid="9442" href="/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a>; VariZIG) for passive immunization against individual viruses is discussed separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'VZV postexposure prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'CMV prevention'</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Respiratory syncytial virus'</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Hepatitis B virus'</a> and  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Protection following exposure'</a> and  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults", section on 'Post-exposure prophylaxis'</a>.)</p><p class="headingAnchor" id="H2353593239"><span class="h2">COVID-19 prevention</span><span class="headingEndMark"> — </span>Pre-exposure prophylaxis, postexposure prophylaxis, vaccination, and other measures to prevent COVID-19 are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H15756477"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor selection</strong> − Donor selection is critical for reducing the risk of complications that increase the risk for infections following allogeneic hematopoietic cell transplantation (HCT) including graft-versus-host disease (GVHD), graft failure, and delayed immune reconstitution  (<a class="graphic graphic_table graphicRef50318" href="/d/graphic/50318.html" rel="external">table 2</a>). (See <a class="local">'Donor selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive regimen</strong> − The posttransplant immunosuppressive regimen after allogeneic HCT should be chosen to strike a balance between sufficient immunosuppression to prevent graft rejection and GVHD as well as to avoid excessive immunosuppression or myelosuppression. In particular, glucocorticoids should be used judiciously because of their profound effect on both innate and acquired immunity, and, when used, doses should be tapered as rapidly as possible to minimize a high risk for infection. (See <a class="local">'Avoidance of excessive immunosuppression and myelosuppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibacterial prophylaxis following HCT </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogeneic HCT with myeloablative conditioning</strong> − We suggest fluoroquinolone prophylaxis for allogeneic HCT recipients who have received myeloablative conditioning regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> (500 or 750 mg orally once daily) and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 or 750 mg orally twice daily) have been studied most extensively, and levofloxacin is favored in patients with increased risk for oral mucositis-related <em>Streptococcus viridans</em> infection. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogenic HCT with reduced-intensity conditioning</strong> − Reduced-intensity and nonmyeloablative conditioning allogeneic HCT is generally associated with a short period of neutropenia and, therefore, there is typically no need for antibiotic prophylaxis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT</strong> − Antibiotic prophylaxis with a fluoroquinolone should be considered for autologous HCT patients transplanted for hematologic malignancies using conditioning regimens that cause significant mucosal injury or in patients who have received or will receive immunosuppressive therapies increasing the risk for bacterial infections. The decision of whether to give antibacterial prophylaxis to autologous HCT recipients should be made on a case-by-case basis. (See <a class="local">'Before engraftment'</a> above and  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'Antibacterial prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD</strong> − For HCT recipients with chronic GVHD, we suggest antibacterial prophylaxis with an agent active against <em>Streptococcus pneumoniae</em> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We continue it for as long as the patient is receiving active immunosuppressive therapy (ie, treatment for GVHD). The choice of antibacterial drug should be based upon local resistance patterns. In areas with a low rate of resistance to penicillin, we favor penicillin. (See <a class="local">'After engraftment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumocystis prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogeneic HCT recipients</strong> − For allogeneic HCT recipients, we recommend that prophylaxis again<em>st Pneumocystis jirovecii</em> (former<em>ly P. carinii</em>) pneumonia (PCP) with <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) be started after engraftment and continued for as long as immunosuppressive therapy is given (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Pneumocystis prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT recipients</strong> − We also recommend PCP prophylaxis for selected autologous HCT recipients, including those with underlying hematologic malignancies such as lymphoma, myeloma, or leukemia, those receiving myeloablative conditioning regimens, those with graft manipulations (eg, CD34 selection), and those who have recently received a purine analog (eg, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> or <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Pneumocystis prophylaxis'</a> above and  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p></p><p class="bulletIndent2">An additional benefit of TMP-SMX prophylaxis is that it prevents toxoplasmosis. (See <a class="local">'Toxoplasma gondii prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of viral and fungal infections</strong> − Strategies to reduce infections from fungi and viruses are important and are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control</strong> − Infection control measures, especially hand hygiene and the use of high efficiency particulate air (HEPA)-filtered patient rooms, can reduce the risk for infection and should be implemented. (See <a class="local">'Infection control measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">Chlorhexidine</a><strong> bathing</strong> − We suggest chlorhexidine bathing for all HCT recipients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Chlorhexidine bathing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cautions with blood product use</strong> − Cytomegalovirus (CMV)-safe blood products (leukocyte filtered or from CMV-seronegative donors) should be used in CMV-seronegative allogeneic HCT recipients whose allografts came from CMV-seronegative donors. (See <a class="local">'Blood products'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> − Routine use of intravenous immunoglobulin (IVIG) has not been found to be effective in preventing infections or other HCT complications or in prolonging survival. We check immunoglobulin G (IgG) levels in allogeneic HCT recipients with bacteremia or recurrent sinopulmonary infections; we suggest administering IVIG to patients with levels &lt;400 mg/dL (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Intravenous immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination</strong> − Immunizations should be given to HCT recipients following the return of immune competence to boost pathogen-specific immunity  (<a class="graphic graphic_table graphicRef91882" href="/d/graphic/91882.html" rel="external">table 4</a>). Other strategies for preventing infections in HCT recipients include pretransplant vaccination of HCT candidates with the usual vaccines that are indicated based upon age, vaccination history, and exposure history; and vaccination of household contacts. (See  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H873387189"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elias Anaissie, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</a></li><li class="breakAll">US Food and Drug Administration. Testing HCT/P donors: Specific requirements. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/TissueSafety/ucm151757.htm (Accessed on November 15, 2023).</li><li><a class="nounderline abstract_t">Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998; 91:3646.</a></li><li><a class="nounderline abstract_t">Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334:281.</a></li><li><a class="nounderline abstract_t">Doan VP, Yeh JC, Gulbis AM, et al. Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:1637.</a></li><li><a class="nounderline abstract_t">De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36:879.</a></li><li><a class="nounderline abstract_t">Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014; :CD005590.</a></li><li><a class="nounderline abstract_t">Chandrasekar PH. Real-time polymerase chain reaction for early diagnosis of toxoplasmosis in stem cell transplant recipients: ready for prime time? Clin Infect Dis 2005; 40:79.</a></li><li><a class="nounderline abstract_t">Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994; 13:549.</a></li><li><a class="nounderline abstract_t">Martino R, Maertens J, Bretagne S, et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis 2000; 31:1188.</a></li><li><a class="nounderline abstract_t">Lim Z, Baker B, Zuckerman M, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect 2007; 54:e83.</a></li><li><a class="nounderline abstract_t">Mele A, Paterson PJ, Prentice HG, et al. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant 2002; 29:691.</a></li><li><a class="nounderline abstract_t">Chandrasekar PH, Momin F. Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team. Bone Marrow Transplant 1997; 19:685.</a></li><li><a class="nounderline abstract_t">de Medeiros BC, de Medeiros CR, Werner B, et al. Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases. Transpl Infect Dis 2001; 3:24.</a></li><li><a class="nounderline abstract_t">Martino R, Bretagne S, Einsele H, et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 2005; 40:67.</a></li><li><a class="nounderline abstract_t">Schmidt M, Sonneville R, Schnell D, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin Infect Dis 2013; 57:1535.</a></li><li><a class="nounderline abstract_t">Jurges E, Young Y, Eltumi M, et al. Transmission of toxoplasmosis by bone marrow transplant associated with Campath-1G. Bone Marrow Transplant 1992; 9:65.</a></li><li><a class="nounderline abstract_t">López-Duarte M, Insunza A, Conde E, et al. Cerebral toxoplasmosis after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2003; 22:548.</a></li><li><a class="nounderline abstract_t">Nakane M, Ohashi K, Tominaga J, et al. Disseminated toxoplasmosis after CD34+-selected autologous peripheral blood stem cell transplantation. Haematologica 2000; 85:334.</a></li><li><a class="nounderline abstract_t">Gonzalez-Vicent M, Diaz MA, Sevilla J, Madero L. Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Ann Hematol 2003; 82:649.</a></li><li><a class="nounderline abstract_t">Foot AB, Garin YJ, Ribaud P, et al. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 1994; 14:241.</a></li><li><a class="nounderline abstract_t">Yusefi M, Arab-Mazar Z, Fallahi S, et al. Diagnosis of Toxoplasma Infection in Allogenic Pre HCTSP Patients Using Molecular Methods. Iran J Parasitol 2022; 17:231.</a></li><li><a class="nounderline abstract_t">Yuen KY, Woo PC. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 2002; 20:51.</a></li><li><a class="nounderline abstract_t">Petersen F, Thornquist M, Buckner C, et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16:199.</a></li><li><a class="nounderline abstract_t">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.</a></li><li><a class="nounderline abstract_t">French CE, McKenzie BC, Coope C, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016; 10:268.</a></li><li><a class="nounderline abstract_t">Bin-Reza F, Lopez Chavarrias V, Nicoll A, Chamberland ME. The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. Influenza Other Respir Viruses 2012; 6:257.</a></li><li><a class="nounderline abstract_t">Smith JD, MacDougall CC, Johnstone J, et al. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ 2016; 188:567.</a></li><li><a class="nounderline abstract_t">Sung AD, Sung JA, Thomas S, et al. Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 2016; 63:999.</a></li><li><a class="nounderline abstract_t">Sokol KA, De la Vega-Diaz I, Edmondson-Martin K, et al. Masks for prevention of respiratory viruses on the BMT unit: results of a quality initiative. Transpl Infect Dis 2016; 18:965.</a></li><li><a class="nounderline abstract_t">Kneifel W, Czech E, Kopp B. Microbial contamination of medicinal plants--a review. Planta Med 2002; 68:5.</a></li><li><a class="nounderline abstract_t">Oliver MR, Van Voorhis WC, Boeckh M, et al. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22:521.</a></li><li><a class="nounderline abstract_t">Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.</a></li><li><a class="nounderline abstract_t">Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598.</a></li><li><a class="nounderline abstract_t">Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37:857.</a></li><li><a class="nounderline abstract_t">Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42:799.</a></li><li><a class="nounderline abstract_t">Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12:661.</a></li><li><a class="nounderline abstract_t">Klumpp TR, Mangan KF, Goldberg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13:1323.</a></li><li><a class="nounderline abstract_t">Demirer T, Ayli M, Dagli M, et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118:1104.</a></li><li><a class="nounderline abstract_t">Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24:5207.</a></li><li><a class="nounderline abstract_t">Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22:416.</a></li><li><a class="nounderline abstract_t">Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009; 27:770.</a></li><li><a class="nounderline abstract_t">Rand KH, Houck H, Ganju A, et al. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 1989; 4:679.</a></li><li><a class="nounderline abstract_t">Bosi A, De Majo E, Guidi S, et al. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. Haematologica 1990; 75:109.</a></li><li><a class="nounderline abstract_t">Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325:110.</a></li><li><a class="nounderline abstract_t">Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134:116.</a></li></ol></div><div id="topicVersionRevision">Topic 1397 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573000" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532022" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002991" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151423" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25269391" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614695" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Real-time polymerase chain reaction for early diagnosis of toxoplasmosis in stem cell transplant recipients: ready for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054907" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073751" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Toxoplasmosis after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16806484" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12180115" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156245" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11429036" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614694" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23994819" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1543952" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transmission of toxoplasmosis by bone marrow transplant associated with Campath-1G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942340" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cerebral toxoplasmosis after autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10702835" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Disseminated toxoplasmosis after CD34+-selected autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928753" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994239" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36032754" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnosis of Toxoplasma Infection in Allogenic Pre HCTSP Patients Using Molecular Methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12111868" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tuberculosis in blood and marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3053457" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068815" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901358" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188875" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952529" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27481873" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27632416" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Masks for prevention of respiratory viruses on the BMT unit: results of a quality initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11842319" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Microbial contamination of medicinal plants--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852973" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388005" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of daily chlorhexidine bathing on hospital-acquired infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579469" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16532017" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762767" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512124" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538555" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199792" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114653" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14691124" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114702" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2555005" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2162799" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052044" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The use of intravenous immune globulin in immunodeficiency diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582312" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical picture and treatment of 2212 patients with common variable immunodeficiency.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
